Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
03 Dezembro 2024 - 10:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
|
Filed by the Registrant ☒
|
|
|
Filed by a Party other than the Registrant ☐
|
Check the appropriate box:
|
☐
|
|
|
Preliminary Proxy Statement
|
|
☐
|
|
|
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
☐
|
|
|
Definitive Proxy Statement
|
|
☒
|
|
|
Definitive Additional Materials
|
|
☐
|
|
|
Soliciting Material under §240.14a-12
|
GALECTIN THERAPEUTICS INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
|
☒
|
|
|
No fee required.
|
|
☐
|
|
|
Fee paid previously with preliminary materials.
|
|
☐
|
|
|
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
|
Galectin Therapeutics (NASDAQ:GALT)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Galectin Therapeutics (NASDAQ:GALT)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
